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Neutrophil-lymphocyte ratio complements
volumetric staging as prognostic factor in
patients treated with definitive
radiotherapy for oropharyngeal cancer
Cédric Panje1, Oliver Riesterer1, Christoph Glanzmann1 and Gabriela Studer1,2*
Abstract
Background: Volumetric tumor staging has been shown as superior prognostic tool compared to the conventional
TNM system in patients undergoing definitive intensity-modulated radiotherapy (IMRT) for head and neck cancer.
Recently, clinical immunoscores such as the neutrophil-lymphocyte ratio (NLR) have been investigated as
prognostic markers in several tumor entities. The aim of this study was to assess the combined prognostic value of NLR
and tumor volume in patients treated with IMRT for oropharyngeal cancer (OC).
Methods: Data on all consecutive patients treated for locally advanced or inoperable OC with IMRT from 2002–2011
was prospectively collected. Tumor volume was assessed based on the total gross tumor volume (tGTV) calculated by
the treatment planning system volume algorithm. The NLR was collected by a retrospective analysis of differential
blood count before initiation of therapy.
Results: Overall, 187 eligible patients were treated with a median IMRT dose of 69.6 Gy. Three-year recurrence-free
survival (RFS) for low, intermediate, high and very high tumor volume groups was 88%, 74%, 62% and 25%,
respectively (p = 0.007). Patients with elevated NLR (>4.68) showed a significantly decreased 3-year RFS of 44% vs. 81%
(p < 0.001) and 3-year OS of 56% vs. 84% (p < 0.001). The NLR remained a significant prognostic factor for RFS and OS
when tested among tumor volume groups. Univariate and multivariate regression analysis confirmed both tumor
volume and NLR as independent prognostic factors. The NLR offered further statistically significant prognostic
differentiation of the small/intermediate/large tumor volume groups.
Conclusion: The NLR remains an independent prognostic factor for patients with OC undergoing radiotherapy
independent of the tumor volume.
Keywords: Radiotherapy, IMRT, Head and neck cancer, Oropharyngeal cancer, Volumetric staging, Neutrophil-
lymphocyte ratio, NLR
Background
Definitive intensity-modulated radiotherapy (IMRT) with
or without concomitant chemotherapy has been estab-
lished as standard treatment for locally advanced and in-
operable oropharyngeal cancer [1]. Several investigators
have previously shown that for non-surgical definitive
IMRT collectives of head neck cancer patients volumetric
staging may provide a prognostic benefit over the conven-
tional Union for International Cancer Control (UICC) sta-
ging system (7th edition) and its T and N categories with
regard to all disease control outcome parameters [2–6]. It
is known for decades that tumor volume and, in conse-
quence, the number of clonogenic cells is one of the most
important predictors for tumor control in radiother-
apy [7, 8]. As anatomically (i.e. surgically) defined sys-
tem, the T and N categories of the standard TNM
system are predominantly based on the extent of
invasion into adjacent structures, number and site of
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involved nodes. Included size parameters are one-
dimensional diameter measurement, which may not cor-
relate well with tumor volume [9]. Consequently, it has
been shown that there is a significant variability in tumor
volume and, in consequence, in outcome within a single T
category in head and neck cancer [10, 11].
More recently, immunological scores such as the
neutrophil-lymphocyte ratio (NLR) have been intro-
duced as prognostic markers for several tumor entities
including various sites of head neck cancer [12–17].
Increased blood neutrophils and tumor associated
neutrophils have been linked to inferior outcome in can-
cer [18], particularly the immunosuppressive subset of
myeloid-derived suppressor cells [19, 20]. In contrary,
several studies have shown that tumor-infiltrating lym-
phocytes may represent increased anti-tumor immunity
with improved local control and long-term prognosis
[21–23]. Blood lymphocytes have consequently been
identified as significant prognostic marker in head and
neck cancer alone as well as part of clinical immuno-
scores such as the neutrophil-lymphocyte ratio [13].
However, it is not clear yet whether an elevated NLR
represents a surrogate parameter for increased tumor
burden in advanced disease [24] or rather tumor-
associated immunological processes which are mainly
volume-independent.
The aim of our study was therefore to explore the cor-
relation between the NLR and the tumor volume in pa-
tients with oropharyngeal cancer undergoing definitive
IMRT. The hypothesis was that the NLR may offer add-
itional prognostic information to the previously tested
volumetric staging system.
Methods
Data on all consecutive patients with locally advanced or
inoperable oropharyngeal cancer (OC) treated with
IMRT at our institution from 2002 to 2011 was pro-
spectively collected. Approval of the Local Ethics
Committee (Cantonal Ethics Committee Zurich, Nr. 709)
is available.
Patients were treated with normofractionated or
slightly hypofractionated (2.11 Gy per fraction) definitive
IMRT over 6–7 weeks and, if there was no medical
contraindication, with weekly cycles of concomitant cis-
platin chemotherapy (40 mg/m2/week) or immunother-
apy with cetuximab as previously prescribed [3, 25].
Recurrence-free survival and overall survival rates were
evaluated. The following clinical parameters were assessed:
age at diagnosis, gender, performance status (Eastern
Cooperative Oncology Group, ECOG), histology, TN tumor
and nodal stage, UICC stage, smoking history, and total
tumor volume. Tumor volume was based on the total
(nodal and primary) gross tumor volume (tGTV) using in-
formation from clinical examination, endoscopy, planning
CT as well as magnetic resonance imaging (MRI) and, if
available, positron emission tomography (PET) [3]. Tumor
volume definition was reviewed by two board-certified
authors (GS and CG). Volumetric three-dimensional
tGTV measurements in cubic centimeters (cm3) were
automatically calculated by the treatment planning
system volume algorithm (Eclipse® V8.5, Varian Medical
Systems, Palo Alto, CA).
Retrospectively collected NLR was obtained from the
most recent available differential blood count after diag-
nosis and before initiation of radiochemotherapy, or, if
applicable, before induction chemotherapy by dividing
the number of neutrophils by the number of lympho-
cytes. Neutrophils and lymphocytes were counted in
109/ml. Patients with acute infections, traumatic injuries,
or invasive biopsies within two weeks before the blood
count were excluded from further analysis.
Statistics
Statistical analysis was performed using R software
(version 3.2) [26] and the packages “survival” and “pro-
dlim”. For comparisons between different groups, the
Chi-square and Mann Whitney U test were used. Spear-
man correlation test was used to analyze correlation be-
tween individual factors. Survival analysis was performed
using the Kaplan-Meier method and the log-rank test to
assess statistical significance. Univariate and multivariate
analysis for prognostic factors were investigated using
the Cox proportional hazard regression model and the
significance level was set to 0.05.
Results
Patient and treatment characteristics
Overall, 194 patients treated with IMRT for oropharyn-
geal cancer at our institution between 2002 and 2011
were identified. Seven patients were excluded due to pri-
mary metastatic disease, missing pretreatment differen-
tial blood count or inflammatory or traumatic disease
within 2 weeks before the pre-IMRT blood count in
order to avoid interference with the NLR. Table 1 shows
demographic and tumor related characteristics for the
remaining 187 eligible patients.
Median IMRT prescription dose to macroscopic tumor
was 69.6 Gy (range 66–72 Gy in 30–35 fractions).
Tumor volume and NLR
Median tGTV was 40 cm3 (range 3–216 cm3). Based on
a previously reported prognostic tumor volumetric
staging [2], 14% of the patients (n = 26) belong to the
low-volume group (<15 cm3), 60% (n = 112) to the
intermediate-volume group (15–70 cm3) and 26%
(n = 49) to the high-volume group (>70 cm3). A previ-
ously reported forth prognostic subgroup of tumors
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>130 cm3 volume [3] was not separately analyzed due to
limited sample size (n = 6).
Median NLR was 3.33 (range 0.91–33.71, lower and upper
quartile 2.34 and 4.68, respectively). In the high-tumor
volume group (> 70 cm3), median NLR was significantly
higher than in the low-volume groups with 3.7 versus 3.12
(p = 0.035) and NRL correlated significantly with the tumor
volume in the whole study population (p = 0.006,
rho = 0.2, Fig. 1).
Outcome related to tumor volume and NLR: Recurrence-free
survival and overall survival
Recurrence-free survival (RFS) for the entire cohort was
72% at three years and remained unchained at five years.
Overall survival (OS) was 77% at three years and 70% at
five years, respectively.
Three-year RFS rates were 88%, 74%, 62% and 25% for
the low-volume (<15 cm3), intermediate-volume (15–
70 cm3), high-volume (>70–130 cm3) and very high-
volume group (>130 cm3), respectively (p = 0.007, see
Fig. 2a-b). Corresponding 5-year RFS rates for the prog-
nostic volume groups were 88%, 74%, 62%, and 25%,
respectively.
There was also a significant correlation of tumor vol-
ume with OS(p < 0.001), with 3-year OS rates for the
prognostic volume groups of 87%, 79%, 74% and 17%,
respectively, and 5-year OS of 87%, 71%, 69% and 17%,
respectively.
Using the upper quartile of 4.68 as cut-off value for
further analysis, the subgroup with elevated NLR
showed a significantly reduced RFS and OS with a differ-
ence for RFS at 3-years of 44% vs. 81% (p < 0.001) and
at 3-years for OS of 56% vs. 84% (p < 0.001), respectively
(Fig. 2c-d).
Table 1 Patient and treatment characteristics
Parameter
Age median 61.6 years (range 36.9–91.4)
Gender 72% male (n = 134)
28% female (n = 53)
Histology 100% squamous cell carcinoma
Oropharyngeal subsite 52% tonsil (n = 97)
40% base of tongue (n = 75)
5% vallecula (n = 9)
2% soft palate (n = 4)
1% posterior wall (n = 2)
T stage (UICC 7th edition) 12% T1 (n = 22)
31% T2 (n = 59)
19% T3 (n = 36)
33% T4 (n = 61)
5% not available/recurrent disease
(n = 9)
N stage (UICC 7th edition) 16% N0 (n = 30)
12% N1 (n = 22)
4% N2a (n = 7)
32% N2b (n = 60)
29% N2c (n = 55)
4% N3 (n = 7)
3% not available/recurrent disease
(n = 6)
UICC Stage (7th edition) 8% Stage II (n = 15)
19% Stage III (n = 35)
67% Stage IVA (n = 122)
4% Stage IVB (n = 7)
2% Recurrent disease (n = 3)
ECOG performance score 80% ECOG 0 (n = 149)
15% ECOG 1 (n = 28)
5% ECOG 2 (n = 9)
Tumor volume (combined nodal
and primary volume); n = events
(any recurrence)
median 40 cm3 (range 3–216 cm3);
overall 52 events
subgroup 1–15 cm3: 14% (n = 26); 3
events
subgroup 15–70 cm3: 60% (n = 112);
28 events
subgroup 70–130 cm3: 23% (n = 43);
17 events
subgroup >130 cm3: 3% (n = 6); 4
events
Smoking status active = 62% (n = 116)
stopped =25% (n = 46)
never smoked = 13% (n = 25)
NLR median 3.33 (range 0.91–33.71)
IMRT dose prescription median 69.6 Gy (66–72 Gy)
single dose 2–2.11 Gy
Concomitant systemic therapy 42% cisplatin weekly (n = 78)
47% reduced number of cisplatin
cycles (n = 87)
7% cetuximab (n = 14)
4% no systemic therapy (n = 7)
Induction chemotherapy 8% of patients (n = 15)
Follow-up median 61.2 months (range 1.7–169)
Fig. 1 Correlation analysis demonstrates a statistically significant
correlation between neutrophil-lymphocyte ratio and total tumor
volume (p = 0.0059, rho = 0.20)
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The NLR remained a significant prognostic factor
when used for each volume group separately: Patients
with elevated NLR (> = 4.68) showed a significantly re-
duced recurrence-free survival in all tumor volume
groups (15 cm3, 15-70 cm3, >70 cm3) as well as a signifi-
cantly inferior overall survival in the high-tumor volume
group and a trend towards significance for the inter-
mediate volume group (Fig. 3). Three-year OS and RFS
for all tumor volume groups with and without elevated
NLR is summarized in Table 2.
Univariate and multivariate regression analysis
Univariate analysis showed significantly increased hazard
ratios for OS and RFS for elevated NLR and tumor vol-
ume, and a significantly reduced hazard ratio for normal
ECOG, and the absence of smoking history. The applica-
tion of full-dose cisplatin chemotherapy (≥ 200 mg per
square meter body surface total dose) was significantly
associated only with OS, and showed a trend towards
significance for RFS (p = 0.052, Table 3).
For multivariate Cox regression analysis, all significant
factors from univariate analysis were included. Tumor
volume, elevated NLR and ECOG status remained sig-
nificant on multivariate testing, whereas chemotherapy
and smoking status did not (Table 4).
Discussion
Volumetric tumor staging has been previously estab-
lished by our group and others as superior prognostic
factor compared to the TNM and UICC staging systems
for patients with locally advanced head and neck cancer
undergoing IMRT [3–5]. As previously reported, we
have identified distinct cut-off values for volumetric sta-
ging in a prospective patient cohort which correlate well
with recurrence-free survival and overall survival [3].
However, there is still a considerable difference in onco-
logical outcome within the pre-defined volume groups,
which supports the use of additional prognostic factors
such as HPV status [27], advanced imaging [28] or clin-
ical immunoscores [15, 29] to determine the individual
risk group of a patient.
Our aim was to analyze the prognostic impact of the
NLR in addition to the previously established volumetric
risk groups in a cohort of patients undergoing definitive
Fig. 2 Recurrence-free survival and overall survival is significantly affected by tumor volume group (a-b) and elevated NLR (> = 4.68) c-d
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radio(chemo)therapy for oropharyngeal cancer. Our hy-
pothesis was that the use of the NLR may further refine
the prognostic volumetric groups which could be con-
firmed based on a significant association with RFS in all
volume groups and with OS in the high tumor volume
group. While several authors have investigated the role
of the NLR alone in head neck cancer [12, 13, 15], this
study is, to our knowledge, the first analysis which com-
bines the prognostic factors of tumor volume and the
NLR.
Our data of a large non-surgical cohort of OC
treated with IMRT confirms the findings of other
a b
c d
e f
Fig. 3 Stratification for NLR in different tumor volume groups. Patients with elevated NLR (> = 4.68) showed a significantly reduced recurrence-free
survival in all tumor volume groups as well as inferior overall survival in the intermediate and high-tumor volume group (a-b: <15 cm3, c-d: 15-70 cm3,
e-f: >70 cm3). NLR resulted in an additional statistically significant prognostic differentiation of the volumetric cohorts with respect to RFS and OS rates
(except of the ‘small tumor volume’ cohort with only 4 events, Fig. 3b)
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groups [12, 13, 15] that one of the most commonly
investigated immunoscores, the NLR, was significantly
associated with recurrence-free survival and overall
survival (see Table 5). Although the NLR showed a
weak, but statistically significant correlation with
tumor volume, the NLR remained a significant inde-
pendent prognostic marker in all tumor volume
subgroups.
Sun et al. [15] previously demonstrated the prognostic
significance of NLR in different UICC-stage-based sub-
groups in nasopharyngeal cancer with no significant im-
pact in stage I and II disease. Similarly, our data for OC
shows a significant correlation with RFS, but not with
OS in small tumor volumes (<15 cm3), which, however,
may also be due to the small sample size (n = 26) and
the limited number of events (n = 4).
Our study was limited by the following facts:
– While the tumor volume was assessed prospectively
since 2004, the NLR was collected retrospectively
from electronic patient records and blood samples
were not taken systematically for this purpose at a
specific time point.
– A general limitation of the NLR is that is affected by
any inflammatory condition such as infections or
invasive procedures as well as by myelosuppressive
conditions such as (induction) chemotherapy which
led to the exclusion of several patients in our analysis.
Future clinical immunoscores may therefore include
more cancer-specific hematological markers and
identify specific leucocyte subgroups. For instance, it
was found that head and neck cancer patients
showed an increased number of immature granulocytes
in the peripheral blood [30] as well as unique
immunophenotypes of immunosuppressive neutrophils
(CD11c bright/CD62L dim/CD11b bright/CD16
bright), which were found in cancer patients but
not in healthy donors [31].
– The major limitation of our study is the fact that
included patients were not systematically screened
for HPV infection, which has been recently established
as strong prognostic factor in OC [27, 32, 33],
but which had not yet been established as standard at
our institution in the investigated period (2002–2011).
A subset analysis of OC patients with available p16
status has recently shown that p16-positive patients
presented with significantly lower NLR, but the NLR
remained a significant prognostic factor both in
the p16-positive and p16-negative group [13].
Additionally, other studies confirmed blood
neutrophils and lymphocytes as strong prognostic
factors in p16-positive OC with significantly
lowered blood neutrophils compared to the
p16-negative group [34, 35]. These findings are
complemented by current immunological research
in head and neck cancer which suggests an increased
anti-tumor immunity, particularly increased
numbers of tumor-infiltrating lymphocytes in p16
positive tumors [36]. Future studies on larger OC
cohorts including p16 status will have to clarify
the role and correlation of p16 status and NLR as
prognostic factors.
Table 3 Univariate Analysis for recurrence-free survival (RFS) and overall survival (OS)
RFS OS
HR Conf. int. p-value HR Conf. int. p-value
Age 1.001 0.9729–1.03 0.942 1.018 0.9932–1.043 0.157
Sex 0.7161 0.3755–1.366 0.308 0.755 0.4312–1.321 0.323
Normal ECOG 0.3812 0.213–0.6823 0.002 0.333 0.2009–0.5518 < 0.001
UICC stage 1.14 0.6254–2.079 0.668 1.163 0.6781–1.996 0.582
No smoking history 0.2293 0.05573–0.9431 0.026 0.314 0.1142–0.8635 0.018
Chemotherapy
(full dose)
0.5653 0.3158–1.012 0.052 0.555 0.335–0.9195 0.021
Tumor volume 1.015 1.008–1.021 < 0.001 1.011 1.005–1.017 < 0.001
NLR 4.059 2.315–7.117 < 0.001 2.311 1.438–3.714 < 0.001
Table 2 Prognostic value of the NLR in different tumor volume risk groups. Cut-off for the NLR was 4.68
3-year recurrence-free survival 3-year overall survival
High NLR Low NLR Hazard ratio P value High NLR Low NLR Hazard ratio P value
Small tumor volume (< 15 cm3) 60% 95% 8.16 0.041 75% 90% 0.95 0.964
Intermediate tumor volume (15–70 cm3) 53% 80% 2.77 0.006 68% 82% 1.95 0.052
High tumor volume (>70 cm3) 28% 74% 5.04 < 0.001 33% 84% 4.16 < 0.001
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Recent advances in cancer research have identified in-
flammatory response as crucial factor for tumor devel-
opment and progression, and, on the other hand, the
presence of tumor-infiltrating lymphocytes as positive
prognostic markers in several tumor entities [37]. The
NLR is a clinical immunoscore which can be easily
deducted from a differential blood count, which is
frequently available in patients receiving chemoradio-
therapy. It has been established as prognostic marker in
several tumor entities [24] including several cohorts of
different head and neck cancer subgroups treated with
surgery or radiotherapy [12, 15, 17, 38].
We decided to use a single, representative cut-off
value for the NLR instead of a subdivision into sev-
eral prognostic groups, as our major aim was to
demonstrate in principle the prognostic impact of
the NLR in each prognostic tumor volume group.
The cut-off value for the NLR in this study of 4.68
is in the same range as in previous publications on
NLR in OC (see Table 5). Additionally, a further
subdivision with several NLR cut-offs would have
resulted in too small subgroups in our single institu-
tion cohort which may not allow to draw a signifi-
cant conclusion.
Table 4 Multivariate analysis for recurrence-free survival (RFS) and overall survival (OS)
RFS OS
HR Conf. int. p-value HR Conf. int. p-value
Normal ECOG 0.5212 0.28515
0.9526
0.521 0.4027 0.2384
0.6804
< 0.001
No smoking history 0.4191 0.09899
1.7739
0.237 0.4887 0.1733
1.3786
0.176
Chemotherapy
(full dose)
0.9337 0.50318
1.7328
0.828 0.8130 0.4757
1.3892
0.449
Tumor volume 1.0111 1.00454
1.0177
0.036 1.0077 1.0016
1.0138
0.013
NLR 3.0218 1.67305
5.4579
< 0.001 1.7333 1.0462
2.8718
0.033
Table 5 Summary of studies investigating the prognostic role of the neutrophil-lymphocyte ratio (NLR) in oropharyngeal cancer (OC)
Study Cohort and treatment NLR cut-off Results p16 status
Rachidi et al. [13] n = 543 HNSCC (170 OC),
any treatment
(2000–2012)
4.39 (upper tertile) - Increased mortality for high NLR (HR = 2.39)
- NLR prognostic factor both in p16-pos. And neg. Pts.
- NLR significantly lower in p16-pos. Patients
yes (89/543)
Charles et al. [29] n = 145 (76 OC),
radio(chemo)therapy
(2005–2012)
5.0 (based on review [39]) - High NLR associated in OC with inferior OS (HR = 4.6)
and RFS (HR = 3.01)
- No subgroup analysis for p16 pos. Pts.
yes (95/145)
Kano et al. [40] n = 285 HNSCC (116 OC),
radiochemotherapy
(2003–2012)
1.92 (based on ROC analysis) - High NLR associated with inferior OS and DFS, but not
significant on multivariate analysis
no
Valero et al. [35] n = 824 (203 OC), any
treatment
(2010–2012)
1.35 and 3.86 (three groups
based on RPA)
- High NLR associated with inferior DSS
- Lower neutrophil number in p16 pos. Pts.
yes (125/824)
Selzer et al. [14] n = 170 (74 OC), primary
radio(chemo)therapy or
radioimmunotherapy
(2002–2012)
5.0 - High NLR associated with inferior median OS
(17 vs. 27 months)
no
Moon et al. [41] n = 153 (51 OC), HNSCC
prospective study
(2010–2012)
not described - High NLR associated with inferior PFS (HR = 2.20)
and OS (HR = 3.22)
no
Huang et al. [34] n = 510, OC,
radio(chemo)therapy
(2000–2010)
not applied (neutrophils and
lymphocytes were analyzed
separately)
- High neutrophils and low lymphocytes are associated
with inferior prognosis
- Reduced neutrophil count and similar lymphocyte
count in p16-pos. Pts.
yes (all)
Young et al. [42] n = 249, OC,
radio(chemo)therapy
(2004–2010)
5.0 - High NLR associated with inferior locoregional control
(HR = 2.072)
no
HNSCC squamous cell carcinoma of the head and neck, pts. patients, ROC receiver-operating characteristic, RPA recursive partitioning analysis, OS Overall survival,
PFS progression-free survival, DFS disease-free survival, DSS disease-specific survival
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Conclusion
In summary, our results demonstrate that the NLR is an
independent prognostic factor for patients with OC
undergoing radio(chemo)therapy regarding RFS in all
tumor volume subgroups and regarding OS in high-
volume groups. The NLR and tumor volume represent
two easily available clinical parameters that impose no
additional diagnostic burden to the patients. Future pro-
spective studies are needed to validate our findings. In
addition, blood assays are needed that identify more spe-
cific subtypes of circulating leukocytes in order to
improve the accuracy of oncological immunoscores.
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